

intensive care unit (ICU) admission, and diarrhea resolution on day of discharge. **Results:** Of the 181 patients, 144 received full treatment, 17 had partial, and 20 had no treatment. Baseline characteristics were similar between groups. No significant difference was found for length of stay or any secondary outcomes (Table 1). Table 2 provides a subgroup of patients who received no treatment vs those receiving partial or full treatment. **Conclusion:** In this study, treatment exposure did not affect clinical outcomes for patients with PCR+/EIA- results, though sample sizes may limit generalizability. Further research is warranted regarding the clinical approach to PCR+/EIA-

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s63–s64

doi:10.1017/ash.2024.183

Presentation Type:

Poster Presentation - Poster Presentation

Subject Category: C. difficile

Impact of Clostridioides difficile Reporting on Antimicrobial Therapy Days Directed at Treatment of C. difficile Infections

Ardath Plache, Memorial Hermann Health System; Edward Septimus, Harvard Medical School and Harvard Pilgrim Health Care Institute and Jamie Thomas, Memorial Hermann Southwest

Background: Previous studies have found that solely relying on molecular testing is likely to result in the overdiagnosis and overtreatment of C. difficile infections (CDI). Comparable outcomes have been demonstrated in patients with a positive molecular test (C. difficile PCR) result and a negative toxin immunoassay (C. difficile toxin) compared to patients without CDI by either testing **Method:** In 2021 Memorial Hermann Healthcare System converted from C. difficile PCR testing only to C. difficile PCR testing with reflex to C. difficile toxin if positive. A previous internal audit revealed that despite this change in testing, patients who were C. difficile PCR positive and C. difficile toxin negative were still receiving treatment. This study aimed to evaluate the impact of C. difficile reporting on the total days of therapy directed at the treatment of CDI of an 11-hospital health care system in patients who testing C. difficile PCR positive/C. difficile toxin negative. **Methods:** Pre-post, multicenter, retrospective, observational study conducted from January 1, 2023 through March 31, 2023 (pre-intervention) and July 1, 2023 through September 31, 2023 (post-intervention) which included hospitalized adult patients with a C. difficile test ordered within the study period. Intervention included a change in reporting of C. difficile PCR positive/C. difficile toxin negative results to display a laboratory comment. The comment notifies providers of the positive C. difficile PCR result while highlighting this probably reflects colonization with C. difficile as the C. difficile toxin is negative and treatment is rarely indicated. **Results:** In total, 989 C. difficile PCR were order in the pre-intervention cohort compared to 1009 in post-intervention. The overall rate of patients that received therapy directed at CDI decreased from 14% to 10% after the implementation of reporting change. Total days of therapy (DOT) also decreased by 29% from 482 to 342. Days of therapy that were administered to patients with C. difficile PCR positive/negative C. difficile toxin test decreased from 183 to 91. **Conclusions:** Adjusting the reporting of C. difficile results led to an overall numerical decrease of antimicrobial DOT directed at CDI treatment. In particular, among patients with a positive C. difficile PCR/C. difficile toxin negative test a 50% reduction in DOT was observed. Further data are required to assess the overall clinical impact of adjusting CDI reporting methods.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s64

doi:10.1017/ash.2024.184

Presentation Type:

Poster Presentation - Poster Presentation

Subject Category: C. difficile

Audit and Feedback to Ordering Providers to Reduce Inappropriate C. difficile Testing and Hospital Onset C. difficile Rate

Elise Martin, VA Pittsburgh Healthcare System; Vanessa Kung, Pittsburgh VA Hospital; Jody Feigel, VA Pittsburgh Healthcare System;

Kristin Nagaro, VA Pittsburgh Healthcare System and Deanna Buehrle, VA Pittsburgh Healthcare System

Background: Inappropriate Clostridioides difficile (C. difficile) laboratory testing is common in hospitals and leads to over diagnosis, unnecessary treatment, and elevated hospital onset C. difficile infection (HO-CDI) metrics. Diagnostic stewardship is essential to avoid inappropriate testing, but limited data exists on optional interventions. **Methods:** A diagnostic stewardship intervention targeting CDI testing comprised of education and prospective audit with feedback was performed at a VA facility (inpatient, outpatient, and long-term care units). Education on appropriate indications for CDI testing was provided in pre-intervention (9/2022 to 5/2023) and intervention periods (6/2023 to 12/2023). During the intervention period, all CDI tests (positive or negative) were audited after completion in real-time by an Infectious Diseases physician and feedback was given to ordering providers and/or their supervising physician (if trainee) for all tests not meeting an appropriate indication. Appropriate indication was defined as ≥ 3 liquid stools in 24 hours or symptoms of fulminant disease. Testing was considered inappropriate if no clinical symptoms, patient received laxatives within 48 hours, test was performed for test-of-cure or within 7 days of a prior test with no clinical change, or delayed testing in patients with diarrhea on admission. The rate of HO-CDI per 10,000 bed days of care (BDOC) per LabID event was compared during the pre-intervention and intervention periods, and ordering appropriateness was compared for all tests and hospital onset tests before (3/2023–5/2023) and after (6/2023–12/2023) feedback was performed. **Results:** After starting audit and feedback, HO-CDI rate decreased from 3.92 per 10,000 BDOC to 0.99 per 10,000 BDOC ($p=0.03$). HO-CDI rate among tests that were inappropriate was 2.19 and 0.80 per 10,000 BDOC during the pre-intervention and intervention periods, respectively ($p=0.40$). Average overall tests per month decreased from 37.8 to 28.1 after the intervention. Rate of all inappropriate tests decreased from 16.25 to 7.96 per 10,000 BDOC ($p=0.04$) and rate of hospital onset inappropriate tests trended toward decrease from 9.29 to 4.77 tests per 10,000 BDOC ($p=0.07$). The most common reasons for inappropriate testing were < 3 episodes of diarrhea in 24 hours (54% pre-intervention, 65% intervention) and laxative use (57% pre-intervention, 45% intervention). No cases of delayed testing leading to worsened disease were identified during the intervention. Cost savings for decreased tests were estimated at \$150–300 per month. **Conclusion:** An intervention comprised of education and real-time audit and feedback of all CDI tests obtained at a VA facility resulted in decreased inappropriate testing and reduced the rate of HO-CDI.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s64

doi:10.1017/ash.2024.185

Presentation Type:

Poster Presentation - Poster Presentation

Subject Category: C. difficile

Leveraging the Electronic Medical Record in C. difficile Diagnostic Stewardship

Vijay Duggirala, The Ohio State University Wexner Medical Center; Jamaal Saleh, The Ohio State University Wexner Medical Center; Justin Smyer, The Ohio State University Wexner Medical Center; Courtney Hebert, The Ohio State University Wexner Medical Center; Christina Liscynsky, The Ohio State University; Nora Colburn, The Ohio State University and Shandra Day, The Ohio State University

Background: Clostridioides difficile PCR is extremely sensitive but cannot differentiate colonization versus active disease. Over diagnosis of C. difficile infection (CDI) has negative consequences including overuse of antibiotics targeting C. difficile, increased hospital-acquired (HA)-CDI rates, and increased healthcare costs. We describe the implementation of a Clinical Decision Support tool embedded in the C. difficile order and the result on testing, HA-CDI rates and healthcare costs. **Methods:** The C. difficile order was updated in June 2023 with 4 dynamic questions that